Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Condition(s) targeted: Acne Vulgaris

Intervention: Dapsone (Drug); Tazarotene (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan

Overall contact:
Allergan Inc, Email: clinicaltrials@allergan.com

A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0. 1% compared with tazarotene cream 0. 1% monotherapy in treating moderate to severe facial acne vulgaris

Study design: Treatment, Randomized, Single Blind (Investigator), Parallel Assignment, Safety/Efficacy Study

Primary outcome: Inflamed lesion counts (papules/pustules)

Secondary outcome:

Investigator global assessment

Overall disease severity

Inflamed lesion counts (nodules)

Non-inflamed lesion counts (open/closed comedones)

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Facial acne vulgaris characterized by the following: 30-100 facial inflammatory

lesions; and 25-100 facial non-inflammatory lesions; stable disease, non-rapidly regressing facial acne vulgaris; and, 3 or more nodules and/or cysts (diameter of 1cm or greater). Female subjects of childbearing potential must have a negative pregnancy test at baseline and practice reliable method of contraception throughout the study

Exclusion Criteria:

- Non-compliance with washout period; history of clinically significant anemia or

hemolysis; skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris; allergy or sensitivity to any component of the test medications

Allergan Inc, Email: clinicaltrials@allergan.com

Fremont, California, United States; Recruiting

Starting date: December 2008
Ending date: March 2010
Last updated: January 30, 2009